2nd Abu Dhabi Brain Conference 2022 Program Book

Scan the QR code for Abbreviated Prescribing Information For adverse events and safety reporting, please send an email: PV-MEA@lilly.com For further information about Lilly and Lilly products, please contact us at the below address: UAE: Bldg. 25 - 6th Floor, Dubai Health Care City, Dubai, UAE, P.O. Box #25319, Tel.: (+971 4) 453 7800, Fax: (+971 4) 436 2399 © 2022 Eli Lilly and Company. All Rights Reserved. PP-GZ-AE-0443 Help your patients achieve more freedom from migraine attacks. 1-4 Emgality is for patients who need more migraine free days. 1,2 REYVOW is for migraine attacks where the pain is disabling. 3,4 References: 1. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. 2. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. 3. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB; on behalf of the COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91 (24):e2222-e2232. 4. Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894-1904.